During the past decade, Ospedale di Macerata conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 2 clinical trials were completed, i.e. on average, 16.7% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 2 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ospedale di Macerata" #1 sponsor was "Consorzio Oncotech" with 3 trials, followed by "Janssen Research & Development, LLC" with 3 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored, "Philogen S.p.A." with 2 trials sponsored and "Air Liquide Santé International" with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ospedale di Macerata" #1 collaborator was "Clinical Research Technology S.r.l." with 2 trials as a collaborator, "Baxalta Innovations GmbH, now part of Shire" with 1 trials as a collaborator, "Eudax S.r.l." with 1 trials as a collaborator, "GlaxoSmithKline" with 1 trials as a collaborator and "Hospira, now a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Ospedale di Macerata" are "Breast Cancer" (3 trials), "Breast Neoplasms" (2 trials), "Metastatic Breast Cancer" (2 trials), "Acute Coronary Syndrome" (1 trials) and "Brain Metastases From Solid Tumors" (1 trials). Many other conditions were trialed in "Ospedale di Macerata" in a lesser frequency.

Most popular intervention types in "Ospedale di Macerata" are "Drug" (17 trials), "Other" (2 trials), "Behavioral" (1 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Erdafitinib" (2 trials), "Exemestane" (2 trials), "Fulvestrant" (2 trials) and "131I-F16SIP Radioimmunotherapy (RIT)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Ospedale di Macerata" are 16 trials for "All" genders, 4 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Ospedale di Macerata". undefined are not yet recruiting, 5 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Ospedale di Macerata, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Ospedale di Macerata, 2 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 2 trials that are defined as “Not Applicable".